BioCryst Pharmaceuticals (BCRX) Stock Heads Up On Patent News

BioCryst Pharmaceuticals BCRX stock news

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is heading up early on in the premarket this morning, and for good reason. The company announced patent news that extends market exclusivity for a key asset. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BCRX Stock Makes A Run After Announcing Patent News

In the press release, BioCryst Pharmaceuticals said that the United States Patent and Trademark Office, or USPTO, has issued a notice of allowance for patent application 16/671,649.

Importantly, this patent, once issued, will extend patent protection for berotralstat (BCX7353) in the United States by four years. BCRX said that the patent covers crystalline salt forms of berotralstat active pharmaceutical ingredient.

In a statement, Jon Stonehouse, CEO At BCRX, had the following to offer:

The extension of U.S. patent protection for berotralstat, through 2039, adds significant value to BioCryst. We look forward to the U.S. approval and launch of oral, once-daily berotralstat later this year.

Why This News Is So Exciting

First and foremost, it’s important to keep in mind that berotralstat isn’t a candidate that’s far from commercialization. In fact, as we speak, the United States FDA is reviewing a New Drug Application, or NDA for the drug.

Through the NDA, BioCryst Pharmaceuticals is hoping to bring oral, once-daily berotralstat to market for the prevention of hereditary angiodema attacks. In fact, investors should know by the PDUFA date, December 3, 2020, whether or not the FDA will allow the drug to hit the market.

So, we’re talking about an asset that could be generating revenue for the company as soon as next year. Should all go well, this is a huge opportunity. In fact, experts suggest that by the year 2025, hereditary angiodema will generate more than $6.5 billion in annual revenues for those that provide treatments.

This patent gives the comapny another four years of market exclusivity, should its treatment hit the market. That’s four more years of market exclusivity with a drug that could potentially generate serious revenue. That makes BCRX a stock that’s well worth watching.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.